TWI616528B - 應用人脂肪衍生的幹細胞增殖血清來源的ｃ型肝炎病毒及其用途 - Google Patents

應用人脂肪衍生的幹細胞增殖血清來源的ｃ型肝炎病毒及其用途 Download PDF

Info

Publication number
TWI616528B
TWI616528B TW104115953A TW104115953A TWI616528B TW I616528 B TWI616528 B TW I616528B TW 104115953 A TW104115953 A TW 104115953A TW 104115953 A TW104115953 A TW 104115953A TW I616528 B TWI616528 B TW I616528B
Authority
TW
Taiwan
Prior art keywords
hcv
hadsc
cells
virus
replication
Prior art date
Application number
TW104115953A
Other languages
English (en)
Chinese (zh)
Other versions
TW201625786A (zh
Inventor
林成龍
Original Assignee
先鋒生藥開發有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 先鋒生藥開發有限公司 filed Critical 先鋒生藥開發有限公司
Publication of TW201625786A publication Critical patent/TW201625786A/zh
Application granted granted Critical
Publication of TWI616528B publication Critical patent/TWI616528B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
TW104115953A 2015-01-07 2015-05-19 應用人脂肪衍生的幹細胞增殖血清來源的ｃ型肝炎病毒及其用途 TWI616528B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
??PCT/CN2015/070243 2015-01-07
PCT/CN2015/070243 WO2016109947A1 (en) 2015-01-07 2015-01-07 Employing human adipose-derived stem cells to propagate serum-derived hepatitis c virus and use thereof

Publications (2)

Publication Number Publication Date
TW201625786A TW201625786A (zh) 2016-07-16
TWI616528B true TWI616528B (zh) 2018-03-01

Family

ID=56355408

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104115953A TWI616528B (zh) 2015-01-07 2015-05-19 應用人脂肪衍生的幹細胞增殖血清來源的ｃ型肝炎病毒及其用途

Country Status (10)

Country Link
US (1) US10273461B2 (enExample)
EP (1) EP3242932A4 (enExample)
JP (1) JP6670322B2 (enExample)
KR (1) KR20170101998A (enExample)
CN (1) CN107208060B (enExample)
AU (1) AU2015376561A1 (enExample)
CA (1) CA2973119A1 (enExample)
HK (1) HK1246824A1 (enExample)
TW (1) TWI616528B (enExample)
WO (1) WO2016109947A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272145A (en) * 2020-01-20 2021-07-29 Stem Cell Medicine Ltd Cosmetic preparations with protein concentrate from a conditioned growth medium of stem cells from adipose tissue
IL278473A (en) 2020-11-03 2022-06-01 Yeda Res & Dev Methods for diagnosing and determining treatment in multiple myeloma
CN114686517A (zh) * 2020-12-25 2022-07-01 中国医学科学院病原生物学研究所 一种hcv四受体转基因合并stat1敲除小鼠的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786207A (en) 1997-05-28 1998-07-28 University Of Pittsburgh Tissue dissociating system and method
CN1166773C (zh) 1997-12-02 2004-09-15 泽恩比奥公司 分离的人脂肪组织衍生的基质细胞
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US20050076396A1 (en) 1999-03-10 2005-04-07 Katz Adam J. Adipose-derived stem cells and lattices
JP2009153383A (ja) * 2006-04-03 2009-07-16 Eci Inc 成熟肝細胞様細胞の製造方法
KR101224504B1 (ko) * 2010-10-01 2013-01-22 가톨릭대학교 산학협력단 크립토탄신온의 신규 용도
GB201119335D0 (en) * 2011-11-09 2011-12-21 Univ Leuven Kath Hepatitis virus infectable stem cells
US20140179775A1 (en) * 2012-02-29 2014-06-26 Mead Johnson Nutrition Company Neurogenesis screening method and uses thereof
US9402710B2 (en) * 2012-07-16 2016-08-02 The Board Of Trustees For The Leland Stanford Junior University Macroporous 3-D scaffolds for tissue engineering

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
內科學誌，20，309-319 *
謝佩真等 (2009) C型肝炎病毒基因分型及其臨床重要性 *
謝佩真等 (2009) C型肝炎病毒基因分型及其臨床重要性。內科學誌，20，309-319。
黃薪睿 (2013) 丙型肝炎病毒可感染人類脂肪幹細胞並做有效率的複製 高雄醫學大學碩士論文 *
黃薪睿 (2013) 丙型肝炎病毒可感染人類脂肪幹細胞並做有效率的複製 高雄醫學大學碩士論文。

Also Published As

Publication number Publication date
EP3242932A4 (en) 2018-05-30
EP3242932A1 (en) 2017-11-15
CA2973119A1 (en) 2016-07-14
AU2015376561A1 (en) 2017-07-27
JP2018501820A (ja) 2018-01-25
KR20170101998A (ko) 2017-09-06
US10273461B2 (en) 2019-04-30
HK1246824A1 (zh) 2018-09-14
JP6670322B2 (ja) 2020-03-18
WO2016109947A1 (en) 2016-07-14
CN107208060A (zh) 2017-09-26
TW201625786A (zh) 2016-07-16
CN107208060B (zh) 2021-06-18
US20180023058A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
Syed et al. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation
Bankwitz et al. Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins
US8663653B2 (en) Efficient cell culture system for hepatitis C virus genotype 2B
Yuan et al. A chimeric humanized mouse model by engrafting the human induced pluripotent stem cell-derived hepatocyte-like cell for the chronic hepatitis B virus infection
Nourbakhsh et al. Arylacetamide deacetylase: a novel host factor with important roles in the lipolysis of cellular triacylglycerol stores, VLDL assembly and HCV production
Shimizu et al. Lipoprotein lipase and hepatic triglyceride lipase reduce the infectivity of hepatitis C virus (HCV) through their catalytic activities on HCV-associated lipoproteins
TWI616528B (zh) 應用人脂肪衍生的幹細胞增殖血清來源的ｃ型肝炎病毒及其用途
Florimond et al. Human hepatic stellate cells are not permissive for hepatitis C virus entry and replication
Shi et al. Transplantation of human umbilical cord blood mesenchymal stem cells improves survival rates in a rat model of acute hepatic necrosis
Boyer et al. TM6SF2 promotes lipidation and secretion of hepatitis C virus in infected hepatocytes
Jin et al. Adipose-derived stem cells show hepatic differentiation potential and therapeutic effect in rats with acute liver failure: Adipose-derived stem cells for acute liver failure
WO2005024004A1 (ja) 間葉系幹細胞の肝細胞への分化方法及び人工ヒト肝臓細胞
Miyaji et al. Bone marrow-derived humoral factors suppress oxidative phosphorylation, upregulate TSG-6, and improve therapeutic effects on liver injury of mesenchymal stem cells
Lu et al. Tree shrew bone marrow–derived mesenchymal stem cells express CD81, OCLN, and miR‐122, facilitating the entire hepatitis C virus life cycle
Aly et al. Strain‐dependent viral dynamics and virus‐cell interactions in a novel in vitro system supporting the life cycle of blood‐borne hepatitis C virus
Li et al. Mouse mesenchymal stem cells from bone marrow differentiate into smooth muscle cells by induction of plaque-derived smooth muscle cells
Tang et al. LncRNA SNHG14 Delivered by Bone Marrow Mesenchymal Stem Cells‐Secreted Exosomes Regulates Osteogenesis and Adipogenesis in Osteoporosis by Mediating the miR‐27a‐3p/LMNB1 Axis
CN100500836C (zh) Hcv病毒体外培养方法
Lee et al. Akt1 is involved in HCV release by promoting endoplasmic reticulum-to-endosome transition of infectious virions
ISKANDAR The Potential Therapeutic Effect of Adult and Young Bone Marrow Derived-Mesenchymal Stem Cells on Hepatocellular Carcinoma in Rat Experimental Model
Meuleman et al. 861 THE LECTIN GRIFFITHSIN HAS ANTIVIRAL ACTIVITY AGAINST HEPATITIS C VIRUS IN VITRO AND IN VIVO
Couteaudier et al. Hypoxia-inducible factor 2 triggers the production of highly infectious native-like hepatitis C virus particles: Couteaudier et al.
Pewkliang et al. Immortalized hepatocyte-like cells: A competent hepatocyte model for studying clinical HCV isolate infection
Coto-Llerena et al. Permissiveness of human hepatocellular carcinoma cell lines for hepatitis C virus entry and replication
Beer Hepatocellular lipid metabolism in Hepatitis C virus infection